Skip to content
Open in App
Abion logo

Abion

web2

Abion is a South Korean biotechnology company developing precision-oncology drug candidates, in...

Symbol · 203400
Company profile

About

Abion is a South Korean biotechnology company developing precision-oncology drug candidates, including small molecules and antibody-based therapies, alongside biomarker-guided strategies for cancer treatment. Its pipeline includes vabametkib, also known as ABN401, an oral c-MET inhibitor being studied in non-small cell lung cancer with MET exon 14 skipping or amplification. The company is also developing antibodies against claudin-3 and TROP2-directed antibody–interferon beta fusion programs, with work spanning discovery, preclinical development and clinical studies. Abion is listed on South Korea’s KOSDAQ market under code 203400, and its published portfolio centers on oncology research and development.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeKOSDAQPrimary symbol: 203400
Expert coverage

Abion profile.

Orbitrum research

Expert coverage

No published expert evaluations are available for this project yet.

Orbitrum Academy

Learn how to read a project assessment